You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here

ClinicalTrials.gov Identifier: NCT02581189

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

    Status Active, enrolment terminated
    Related Conditions
    Chronic Hepatitis C

Enrollment Details

Phases: 

  • I
  • II
  • III
  • IV
Study Type:  Observational

This is a type IV phase trial.

Protocol ID
P15-651

Brief summary

Top

This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free ABBVIE REGIMEN ± RBV in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Canada.

Participant Attributes :
  • Male and Female
  • Ages 18 Years to 99 Years

Canada: 33

0
Vancouver, BC
1
Vancouver, BC
2
Brampton, ON
3
New Westminster, BC
4
Toronto, ON
5
Vancouver, BC
6
Moncton, NB
7
Montreal, QC
8
Saint John, NB
9
Winnipeg, MB
10
Belleville, ON
11
Fredericton, NB
12
Saskatoon, SK
13
Montreal, QC
14
Calgary, AB
15
Barrie, ON
16
Vancouver, BC
17
Hamilton, ON
18
Victoria, BC
19
Halifax , NS
20
Quebec, QC
21
Montreal, QC
22
Toronto, ON
23
Sherbrooke, QC
24
Montreal, QC
25
Montreal, QC
26
Regina, SK
27
Toronto, ON
28
Victoria, BC
29
North Bay, ON
30
Toronto, ON
31
Richmond Hill, ON
32
Prince George, BC
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.
    ?

    Observational Model

    Cohort

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
    ?

    Time Perspective

    Prospective

    • Confirmed, CHC, genotype 1 or 4, treatment-naïve or -experienced participants receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV
    • If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)
    • Participants must voluntarily sign and date a participant authorization to use and/or disclose his/her anonymized health data prior to inclusion into the study

     

    Patient participating or intending to participate in a concurrent interventional therapeutic trial

More on this trial

Clinical Trials.gov